Athersys, Inc. (ATHX) shares are down more than 50% in premarket trading after the biotech company reported Friday that a study of its MultiStem ischemic...
Athersys (ATHX) shares slumped 44% after the company said its partner reported topline data from a study on ischemic stroke. Evofem Biosciences (EVFM)...
...
Athersys (ATHX) on Thursday filed a shelf registration statement for the potential sale of up to $250 million of its securities from time to time. The...
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 05/12/2022 424B5 |
| Chief Executive Officer & Director | Daniel A. Camardo |
| President & Chief Operating Officer | William B. J. Lehmann |
| Chief Financial & Accounting Officer | Ivor MacLeod |
| Director, Chief Scientific Officer & Executive VP | John J. Harrington |
| Price Open | $0.22 |
| Previous Close | $0.21 |
| 52 Week Range | $0.20 - 1.81 |
| Market Capitalization | $50.5 M |
| Shares Outstanding | 252.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.35 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -981.52% |
| Return on Equity | -429.24% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
